ALAN W DUNTON
CIK 1304773 · Chief Exec Officer & President · last filed 2026-01-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$622.9K
Companies
6
Total Filings
123
Lifetime Open-Market Net
$3.59M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRMD | Director | 70,703 | $7.35 | $519.7K | -$338.3K | 16 | 2026-01-27 |
| OGEN | Director | 854 | $0.50 | $424 | -$186.7K | 28 | 2025-12-15 |
| PTN | Director | 13,382 | $7.68 | $102.8K | $4.02M | 32 | 2025-12-11 |
| MNOV | Director | — | $1.33 | — | $0 | 4 | 2010-06-15 |
| PANACOS PHARMACEUTICALS, INC. (PANC) Delisted | Chief Exec Officer & President | 240,865 | — | — | $96.3K | 8 | 2008-05-05 |
| Adams Respiratory Therapeutics, Inc. (ARXT) Delisted | Director | 0 | — | — | $0 | 7 | 2008-01-30 |
Recent Filings · Page 2 of 13
123 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-06 | OGEN | Notice (144) | −66 | -$22 | EDGAR |
| 2024-09-20 | OGEN | Grant (A) | — | $0 | EDGAR |
| 2024-07-17 | PTN | Grant (A) | +12,000 | $0 | EDGAR |
| 2024-07-16 | PTN | Grant (A) | +12,000 | $0 | EDGAR |
| 2024-03-20 | CRMD | Grant (A) | — | $0 | EDGAR |
| 2023-12-18 | CRMD | Buy (P) | +6,000 | $20.2K | EDGAR |
| 2023-12-06 | PTN | Notice (144) | −160 | -$402 | EDGAR |
| 2023-12-06 | PTN | Sell (S) | −200 | -$496 | EDGAR |
| 2023-12-01 | PTN | Notice (144) | −200 | -$410 | EDGAR |
| 2023-08-10 | OGEN | Grant (A) | +25,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.